uniQure (NASDAQ:QURE) Receives $17.00 Consensus PT from Brokerages

Shares of uniQure (NASDAQ:QURE) have been given an average recommendation of “Moderate Buy” by the six analysts that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $17.00.

Several research analysts have commented on QURE shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 target price on shares of uniQure in a report on Wednesday, November 6th. StockNews.com raised shares of uniQure to a “sell” rating in a research note on Thursday, October 17th. Royal Bank of Canada lowered their target price on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research note on Wednesday, November 6th. Finally, The Goldman Sachs Group decreased their target price on uniQure from $10.00 to $9.00 and set a “neutral” rating for the company in a research note on Wednesday, November 6th.

uniQure Stock Performance

uniQure stock opened at $6.05 on Wednesday. The business has a 50 day moving average of $5.95 and a 200-day moving average of $5.98. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. uniQure has a 1 year low of $3.73 and a 1 year high of $11.35. The company has a market capitalization of $294.90 million, a P/E ratio of -1.22 and a beta of 0.90.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.21. The firm had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. On average, equities research analysts predict that uniQure will post -3.81 earnings per share for the current year.

Institutional Trading of uniQure

Several large investors have recently made changes to their positions in the company. RTW Investments LP acquired a new position in uniQure during the 3rd quarter worth approximately $49,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 3,663 shares in the last quarter. Atria Investments Inc acquired a new position in shares of uniQure during the third quarter worth approximately $53,000. Quarry LP bought a new position in shares of uniQure in the 3rd quarter worth $58,000. Finally, Vanguard Personalized Indexing Management LLC grew its position in uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 2,306 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.